Clinical Trial Update: Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) [Phase 4]

View source ↗

Summary

Phase 4 immunogenicity and reactogenicity study of Boostrix and Boostrix-IPV has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)
• Boostrix-IPV (diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Tetanus | Phase 4 | Status: COMPLETED